1. Home
  2. ADPT vs APAM Comparison

ADPT vs APAM Comparison

Compare ADPT & APAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$16.04

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Artisan Partners Asset Management Inc.

APAM

Artisan Partners Asset Management Inc.

HOLD

Current Price

$42.59

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
APAM
Founded
2009
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.1B
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
ADPT
APAM
Price
$16.04
$42.59
Analyst Decision
Strong Buy
Buy
Analyst Count
9
4
Target Price
$17.78
$47.00
AVG Volume (30 Days)
1.9M
609.7K
Earning Date
02-05-2026
02-03-2026
Dividend Yield
N/A
9.09%
EPS Growth
N/A
10.70
EPS
N/A
4.05
Revenue
$276,976,000.00
$1,196,700,000.00
Revenue This Year
N/A
$8.46
Revenue Next Year
$23.05
$6.70
P/E Ratio
N/A
$10.52
Revenue Growth
54.77
7.64
52 Week Low
$6.26
$32.75
52 Week High
$20.76
$48.50

Technical Indicators

Market Signals
Indicator
ADPT
APAM
Relative Strength Index (RSI) 35.89 41.72
Support Level $14.85 $42.51
Resistance Level $17.98 $46.53
Average True Range (ATR) 1.10 1.57
MACD -0.35 -0.23
Stochastic Oscillator 14.24 4.50

Price Performance

Historical Comparison
ADPT
APAM

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About APAM Artisan Partners Asset Management Inc.

Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. In addition to its equity strategies, customers may invest in a fixed-income strategy. Strategies are often distributed to customers ranging from retail investors to institutional investors through specialized channels.

Share on Social Networks: